Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside with and without the CHK1 Inhibitor MK-8876 in Adults with Relapsed and Refractory Acute Myelogenous Leukemia

Jonathan Allen Webster, MD, Raoul Tibes, MD PhD, Amanda Blackford, ScM, Lawrence Morris, MD, Mrinal M Patnaik, MBBS, Lihua Wang, PhD, Melanie Rebechi, BS, Jacqueline Greer, RN, Mark R Litzow, MD, Larry Karnitz, PhD, Gary L. Rosner, Austin Doyle, MD, Scott H. Kaufmann, MD PhD, Judith E Karp, MD, B. Douglas Smith, MD

Blood (2015) 126 (23): 2563.

https://doi.org/10.1182/blood.V126.23.2563.2563

Published: 2015

Journal Articles

A Phase I Study Of The Histone Deacetylase Inhibitor Entinostat Plus Clofarabine For Philadelphia Chromosome Negative, Poor Risk (Newly Diagnosed Older Adults or Adults with Relapsed and Refractory Disease) Acute Lymphoblastic Leukemia Or Bilineage/Biphenotypic Leukemia

Hetty E Carraway, MD, MBA, Judith E. Karp, MD, Ivana Gojo, MD, Keith W. Pratz, MD, Nilanjan Ghosh, MD, PhD, Steven D. Gore, MD, Margaret M. Showel, MD, Mark Levis, MD, PhD, B. Douglas Smith, Jacqueline Greer, James G. Herman, MD, Lia Gore, MD, Min-Jung Lee, PhD, Sunmin Lee, PhD, Peter Ordentlich, PhD, Richard Piekarz, MD, PhD, Jane Trepel, PhD

Blood (2013) 122 (21): 1427.

https://doi.org/10.1182/blood.V122.21.1427.1427

Published: 2013

Journal Articles

RASGRP1:APTX Gene Expression Ratio Enriches for Responders to the Combination of Tipifarnib and Etoposide in Elderly Newly Diagnosed AML.

Mitch Raponi, PhD, Tatiana Vener, PhD, Carlo Derecho, MSc, Jacqueline Greer, RN, BSN, Sami Malek, MD, John Palma, PhD, Judith E Karp, MD

Blood (2009) 114 (22): 4154.

https://doi.org/10.1182/blood.V114.22.4154.4154

Published: 2009

Journal Articles

Human Immunodeficiency Virus (HIV)-Associated Acute Myeloid Leukemia (AML) in the Era of Highly Active Antiretroviral Therapy (HAART): High Complete Remission Rate, but Poor Tolerance of Consolidation Therapy and Short Disease-Free Survival.

Michael W Evans, MD, MPH, Anthony Sung, MD, Ivana Gojo, MD, Michael L Tidwell, RN, CRNP, Jacqueline Greer, RN, BSN, Mark Levis, Judith Karp, Maria R Baer, MD

Blood (2009) 114 (22): 4126.

https://doi.org/10.1182/blood.V114.22.4126.4126

Published: 2009

Journal Articles

A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias

Judith E. Karp, Rebecca M. Ricklis, Kumudha Balakrishnan, Janet Briel, Jacqueline Greer, Steven D. Gore, B. Douglas Smith, Michael A. McDevitt, Hetty Carraway, Mark J. Levis, Varsha Gandhi

Blood (2007) 110 (6): 1762–1769.

https://doi.org/10.1182/blood-2007-03-081364

Published: 2007

Journal Articles

Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias

Ivana Gojo, Anchalee Jiemjit, Jane B. Trepel, Alex Sparreboom, William D. Figg, Sandra Rollins, Michael L. Tidwell, Jacqueline Greer, Eun Joo Chung, Min-Jung Lee, Steven D. Gore, Edward A. Sausville, James Zwiebel, Judith E. Karp

Blood (2006) 109 (7): 2781–2790.

https://doi.org/10.1182/blood-2006-05-021873

Published: 2006

Journal Articles

Phase I Clinical-Laboratory Trial of Clofarabine (CLO) Followed by Cyclophosphamide (CY) for Adults with Refractory Acute Leukemias: Evidence for Enhanced DNA Damage.

Judith E. Karp, MD, Rebecca M. Ricklis, MBA, Jacqueline Greer, RN, Janet Briel, RN, Mark J. Levis, MD,PhD

Blood (2006) 108 (11): 1963.

https://doi.org/10.1182/blood.V108.11.1963.1963

Published: 2006

Journal Articles

Active Oral Regimen for Elderly Adults with Newly Diagnosed Acute Myelogenous Leukemia (AML): Phase I Trial of Oral Tipifarnib (T) Combined with Oral Etoposide (E) for Adults ≥Age 70 Who Are Not Candidates for Traditional Cytotoxic Chemotherapy (TCC).

Judith E. Karp, MD, Eric J. Feldman, MD, Lawrence Morris, MD, Jacqueline Greer, RN, Valerie Ironside, RN, B. Douglas Smith, MD, Ellen Ritchie, MD, Steven D. Gore, MD, Mark J. Levis, MD,PhD, Scott H. Kaufmann, MD,PhD, Sami Malek, MD, John J. Wright, MD,PhD

Blood (2006) 108 (11): 426.

https://doi.org/10.1182/blood.V108.11.426.426

Published: 2006

Journal Articles

A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia

Jeffrey E. Lancet, Ivana Gojo, Jason Gotlib, Eric J. Feldman, Jacqueline Greer, Jane L. Liesveld, Laura M. Bruzek, Lawrence Morris, Youn Park, Alex A. Adjei, Scott H. Kaufmann, Elizabeth Garrett-Mayer, Peter L. Greenberg, John J. Wright, Judith E. Karp

Blood (2006) 109 (4): 1387–1394.

https://doi.org/10.1182/blood-2006-04-014357

Published: 2006

Journal Articles

Tipifarnib (Zarnestra, R115777) as Maintenance Therapy for Adults in Complete Remission (CR) Following Induction and Consolidation Therapies for Poor-Risk Acute Myelogenous Leukemia (AML): A Phase II Trial.

Judith E. Karp, MD, Ivana Gojo, MD, Jacqueline Greer, R.N., B. Douglas Smith, MD, Maureen Klein, R.N., Jeffery E. Lancet, MD, Steven D. Gore, MD, Lawrence Morris, MD, Alain Thibault, MD, Mary Ellen Rybak, MD, John J. Wright, MD, PhD

Blood (2005) 106 (11): 2783.

https://doi.org/10.1182/blood.V106.11.2783.2783

Published: 2005

Journal Articles

Phase II Clinical Trial of Flavopiridol (FL) Followed by ara-c and Mitoxantrone (AM) for Adults with Relapsed and Refractory Acute Leukemias.

Judith E. Karp, MD, B. Douglas Smith, MD, Jacqueline Greer, R.N., Janet Briel, R.N., Mark J. Levis, MD/PhD, Michael A. McDevitt, MD/PhD, Steven D. Gore, MD, A. Dimitrios Colevas, MD

Blood (2005) 106 (11): 2784.

https://doi.org/10.1182/blood.V106.11.2784.2784

Published: 2005

Journal Articles

Tipifarnib (ZARNESTRA TM in Previously Untreated Poor-Risk AML of the Elderly: Updated Results of a Multicenter Phase 2 Trial.

Jeffrey E. Lancet, MD, Jason Gotlib, MD, Ivana Gojo, MD, Eric J. Feldman, MD, Lawrence Morris, MD, Alain Thibault, MD, Jane L. Liesveld, MD, Jacqueline Greer, RN, Kathleen Dugan, RN, Mitch Raponi, PhD, John J. Wright, MD, PhD, Peter L. Greenberg, MD, Judith E. Karp, MD

Blood (2004) 104 (11): 874.

https://doi.org/10.1182/blood.V104.11.874.874

Published: 2004

NARROW

Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside with and without the CHK1 Inhibitor MK-8876 in Adults with Relapsed and Refractory Acute Myelogenous Leukemia

A Phase I Study Of The Histone Deacetylase Inhibitor Entinostat Plus Clofarabine For Philadelphia Chromosome Negative, Poor Risk (Newly Diagnosed Older Adults or Adults with Relapsed and Refractory Disease) Acute Lymphoblastic Leukemia Or Bilineage/Biphenotypic Leukemia

RASGRP1:APTX Gene Expression Ratio Enriches for Responders to the Combination of Tipifarnib and Etoposide in Elderly Newly Diagnosed AML.

Human Immunodeficiency Virus (HIV)-Associated Acute Myeloid Leukemia (AML) in the Era of Highly Active Antiretroviral Therapy (HAART): High Complete Remission Rate, but Poor Tolerance of Consolidation Therapy and Short Disease-Free Survival.

A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias

Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias

Phase I Clinical-Laboratory Trial of Clofarabine (CLO) Followed by Cyclophosphamide (CY) for Adults with Refractory Acute Leukemias: Evidence for Enhanced DNA Damage.

Active Oral Regimen for Elderly Adults with Newly Diagnosed Acute Myelogenous Leukemia (AML): Phase I Trial of Oral Tipifarnib (T) Combined with Oral Etoposide (E) for Adults ≥Age 70 Who Are Not Candidates for Traditional Cytotoxic Chemotherapy (TCC).

A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia

Tipifarnib (Zarnestra, R115777) as Maintenance Therapy for Adults in Complete Remission (CR) Following Induction and Consolidation Therapies for Poor-Risk Acute Myelogenous Leukemia (AML): A Phase II Trial.

Phase II Clinical Trial of Flavopiridol (FL) Followed by ara-c and Mitoxantrone (AM) for Adults with Relapsed and Refractory Acute Leukemias.

Tipifarnib (ZARNESTRA TM in Previously Untreated Poor-Risk AML of the Elderly: Updated Results of a Multicenter Phase 2 Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only